Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 120HER2-positive Breast Cancer 10Stomach Neoplasms 9Neoplasm Metastasis 6Neoplasms 4Inflammatory Breast Neoplasms 4Esophageal Neoplasms 3Adenocarcinoma Of Esophagus 3Parkinson Disease 4, Autosomal Dominant Lewy Body 2Invasive Breast Cancer 2HER2-positive Metastatic Breast Cancer 2HER2-positive Early Breast Cancer 2Colonic Neoplasms 2Biliary Tract Neoplasms 2Solid Tumors 1Resectable HER2-positive Breast Cancer 1Patient Preference 1Pathologic Complete Response 1Osteitis Deformans 1Metastatic HER2-positive Breast Cancer 1HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients 1HER2-positive Gastric Cancer 1HER2-positive Carcinoma of Breast 1HER2-positive Advanced Breast Cancer 1HER2+ Breast Cancer 1HER2 Positive Early or Locally Advanced Breast Cancer 1HER2 Positive Early Breast Cancer 1Endometrial Neoplasms 1Early-stage or Locally Advanced HER2-positive Breast Cancer 1Early or Locally Advanced HER2-positive Breast Cancer 1

Interventions

fluzoparib 1exemestane 1dalpiciclib 1Trastuzumab 1Letrozole 1Ga(III)-DOTATOC 1Everolimus 1Docetaxel 1Aromatase Inhibitors 1Anastrozole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Breast Cancer Metastatic × Trastuzumab × Clear all
NCT05301010 2023-02-27

Clinical Trial to Assess Efficacy and Safety of NNG-TMAB (Trastuzumab) on Recurrent or Metastatic Breast Cancer Patients

Nanogen Pharmaceutical Biotechnology Joint Stock Company

Phase 3 Completed
128 enrolled
Breast

Breast Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡